Collegium Pharmaceutical annual gross margin
2018
2019
2020
2021
2022
2023
2024
2025
Collegium Pharmaceutical's gross margin was 59.35% for fiscal 2025.
View full Collegium Pharmaceutical company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 59.35% | −0.41 pp |
| 2024 | 2024-12-31 | 59.76% | +2.21 pp |
| 2023 | 2023-12-31 | 57.55% | +12.39 pp |
| 2022 | 2022-12-31 | 45.15% | −9.25 pp |
| 2021 | 2021-12-31 | 54.40% | −3.61 pp |
| 2020 | 2020-12-31 | 58.01% | +23.28 pp |
| 2019 | 2019-12-31 | 34.73% | −6.19 pp |
| 2018 | 2018-12-31 | 40.92% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 55.18% | −2.47 pp |
| Q1 2026 | 2026-03-31 | 60.59% | +5.83 pp |
| Q4 2025 | 2025-12-31 | 62.49% | +8.47 pp |
| Q3 2025 | 2025-09-30 | 61.70% | +0.94 pp |
| Q2 2025 | 2025-06-30 | 57.65% | −4.85 pp |
| Q1 2025 | 2025-03-31 | 54.75% | −8.36 pp |
| Q4 2024 | 2024-12-31 | 54.02% | −9.17 pp |
| Q3 2024 | 2024-09-30 | 60.76% | +2.02 pp |
| Q2 2024 | 2024-06-30 | 62.51% | +8.04 pp |
| Q1 2024 | 2024-03-31 | 63.11% | +9.64 pp |
| Q4 2023 | 2023-12-31 | 63.19% | +24.78 pp |
| Q3 2023 | 2023-09-30 | 58.75% | +12.42 pp |
| Q2 2023 | 2023-06-30 | 54.47% | +12.08 pp |
| Q1 2023 | 2023-03-31 | 53.47% | −4.44 pp |
| Q4 2022 | 2022-12-31 | 38.41% | +43.28 pp |
| Q3 2022 | 2022-09-30 | 46.33% | −12.16 pp |
| Q2 2022 | 2022-06-30 | 42.38% | −18.19 pp |
| Q1 2022 | 2022-03-31 | 57.90% | −5.48 pp |
| Q4 2021 | 2021-12-31 | −4.87% | −62.94 pp |
| Q3 2021 | 2021-09-30 | 58.49% | −2.38 pp |
| Q2 2021 | 2021-06-30 | 60.57% | −1.39 pp |
| Q1 2021 | 2021-03-31 | 63.38% | +12.42 pp |
| Q4 2020 | 2020-12-31 | 58.07% | +24.23 pp |
| Q3 2020 | 2020-09-30 | 60.87% | +24.97 pp |
| Q2 2020 | 2020-06-30 | 61.96% | +26.80 pp |
| Q1 2020 | 2020-03-31 | 50.96% | +16.93 pp |
| Q4 2019 | 2019-12-31 | 33.85% | — |
| Q3 2019 | 2019-09-30 | 35.90% | — |
| Q2 2019 | 2019-06-30 | 35.16% | — |
| Q1 2019 | 2019-03-31 | 34.02% | — |
Over the last five reported fiscal years, Collegium Pharmaceutical's gross margin increased from 58.01% to 59.35%, a change of +1.34 percentage points. The latest reported quarter, Q2 2026, shows 55.18%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Collegium Pharmaceutical filings at SEC.gov ↗